(Date:11/9/2009)...v. 9 BioMed Realty Trust...any has received commitments from lenders to incre...f credit by $65 million to an aggregate of $665 mi...acility. The weighted-average effective interest ...of September 30, 2009. The maturity date remains A...
(Date:11/9/2009)...Nov. 9 CEL-SCI Corporati...neth S. Rosenthal, Professor of Immunology and Mic...e of Medicine and Pharmacy, reported on work condu...land Clinic and CEL-SCI on CEL-SCI,s LEAPS vaccine...Cbio Vaccine: "All Things Considered" Conference i...
(Date:11/8/2009)... As global temperatures and energy costs continue ...o a sustainable future. An attractive replacemen...ished online in Genome Research ( www.genome.org... of bioethanol-producing microorganisms, uncoverin...g new technologies needed to implement production ...
(Date:11/6/2009)...., Nov. 6 BioSpecifics T...tical company developing first-in-class collagenas...sults for the third quarter ended September 30, 20...mber of this year, the FDA,s Arthritis Advisory Co..., the approval of XIAFLEX(TM) for the treatment of...
Breaking Biology Technology:BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 2BioMed Realty Trust Receives Commitments to Expand Unsecured Line of Credit to $665 Million 3CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 2CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response 3Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6.... 17 National Stem,Cell Holding, Inc. (Other OTC:...n, financial information, quotations and press rel...nk Sheets., OTCIQ is a secure, web-based portal t... and services to facilitate communication with the... gather market,intelligence, and inspire better co...
...7 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: V...-II, a,confirmatory clinical trial which is design...l of the Celacade(TM) System for the treatment of ...ompany has been working diligently on the ACCLAIM-... Committee led by James B. Young,MD, Chairman, Div...
...ll Enhance Quality and Speed Image Transfer at Low...Compliance, BOSTON, Dec. 17 AG Mednet, the world...nced it has been selected by,Southwest Oncology Gr...ncer,clinical trials cooperative groups in the Uni...nd HIPAA-compliant image network. With the AG,Medn...
Other Biology Technology:National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC 2Vasogen Provides an Update on ACCLAIM-II Preparations 2Vasogen Provides an Update on ACCLAIM-II Preparations 3Vasogen Provides an Update on ACCLAIM-II Preparations 4AG Mednet to Provide Image Network for Southwest Oncology Group 2Mouse Anti-Human CRKRS Monoclonal Antibody, Unconjugated, Clone 3C1 from Abnova Corporation
...lyclonal antibody raised against a partial recombi... 250 a.a) partial recombinant protein with GST tag...ARDSAQAKRKYQEASKDKDRDKAKDKYVRSLWKLFAHHNRYVLGVRAAQL...REMAA Accession: BC035357 Protein Accession...
Mouse Anti-PPP4C Polyclonal Antibody, Unconjugated from Abnova Corporation
Mouse Anti-Human CAPG Monoclonal Antibody, Unconjugated, Clone 6D6 from Abnova Corporation
Biology Products: